Sign up now and fund within 24h to get free stock in NKE, GPRO, DBX or a mystery stock. T&Cs apply.

VACC

VACCITECH PLC

1 day chart

About VACC

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

Buy US stocks in Australia with $0 brokerage and trade VACC today!

Market Capitalisation

$89.51M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

9.33K

High today

$2.48

Low today

$2.31

Open price

$2.34

52-week high

$12.80

52-week low

$2.08


What does Vaccitech do? 

No prizes for guessing: Vaccitech makes vaccines. More accurately, it is a clinical stage T cell immunotherapy and vaccine company, developing products to treat and prevent infectious diseases and cancers. Founded in 2016, Vaccitech is a spin-out company from the University of Oxford's Jenner Institute.

As of the end of FY2021, Vaccitech has a large pipeline of clinical and preclinical stage therapeutic and prophylactic programs.

Its therapeutic program consists of:

  • VTP-300 for the treatment of chronic hepatitis B infection (CHB) — in Phase 2

  • VTP-200 for the treatment of human papilloma virus infection (HPV)  — in Phase 2 

  • VTP-850 for the treatment of prostate cancer — in Phase 2

  • VTP-600 for the treatment of non-small cell lung cancer (NSCLC) — in Phase 1

Its prophylactic program includes:

  • VTP-400 for the prevention of herpes zoster (shingles)  — in Phase 1

  • VTP-500 for the prevention of Middle East respiratory syndrome (MERS) — Preclinical 

Vaccitech also developed Vaxzevria (VTP-900) in partnership with Oxford University Innovation. The drug is now authorised for the prevention of COVID-19 infection in 90 countries.

How does Vaccitech make money?

Vaccitech receives money from three revenue streams and reports in a single segment.

Service revenue 

Vaccitech’s earnings for this stream come from providing research services. The company has recently worked with biotech company Enara Bio to provide research on up to six vaccine products based on antigens discovered by Enara.

Vaccitech has also worked with BARDA, a division of the U.S. Department of Health and Human Services in the Office of the Assistant Secretary for Preparedness and Response. Vaccitech is helping BARDA develop a new influenza prophylactic.

Licence revenue

Vaccitech receives a share of certain regulatory and sales milestones and royalties on net sales of Vaxzevria. The company also receives a portion of Vaxzevria sublicensing income from AstraZeneca who has exclusive worldwide rights to develop and commercialise the vaccine.

Vaccitech’s share of royalties on the net sales of Vaxzevria is approximately 1.4%.

Research grants and contracts

Vaccitech receives funding from the government to support its therapeutic and prophylactic research.

Is Vaccitech a profitable company?

No, Vaccitech is not profitable at this time.

The company reported net losses of US$18m and US$51m for FY2020 and FY2021. At the end of FY2021, the company had accumulated a deficit of US$108.6m.

In their most recent annual report, Vaccitech stated: 

“We are a clinical-stage biopharmaceutical company with a limited operating history, and we are in the early stages of our development efforts.”

Should I buy VACC stock?

The VACC stock price hit a high of US$17.99 not long after the company went public in May 2021. Shortly afterwards, the stock began to fall. As of March 2022, VACC has fallen over 70% to a low of US$4.47.

For many investors, VACC is a highly speculative play. The clinical-stage company is losing money and there’s no way to tell if Vaccitech’s immunotherapeutic products or vaccines will work.

Vaccitech has warned:

“Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, obtain marketing authorization and become commercially viable.”

Is VACC an ADR?

Yes, as Vaccitech is a British company, VACC stocks are ADRs. These ADRs are listed on the Nasdaq.

What is an ADR?

An ADR is an American Depository Receipt. ADRs are equities that trade on American exchanges but represent stocks in a foreign corporation. ADRs make it easier for non-U.S. companies to access U.S. capital markets.

Who owns VACC stock?

As of March 2022, Vaccitech’s top five largest shareholders are Oxford Science Enterprises (23.66%), M&G Alternatives Investment Management (11.05%), M&G Investment Management Limited (5.85%), GV Management Company (4.58%) and Tencent Holdings Limited (3.84%).

Vaccitech C-level figures William Enright (CEO), Thomas Evans (Chief Scientific Officer) and Graham Griffiths (Chief Business Officer) are also significant shareholders holding 3.38%, 0.34% and 0.31%, respectively.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.


Stake logo
Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2022 Stake. All rights reserved.